MDX1106 ONO-4538

DRUG3 trials

Sponsors

Bristol-Myers Squibb Services Unlimited Company, Bristol Myers Squibb International Corporation

Conditions

Metastatic Castration-Resistant Prostate CancerSubjects with High Risk Invasive Urothelial Carcinomalung cancer; kidney cancer; melanoma; liver cancer; colorectal cancer; bladder cancer

Phase 1

CA209-8KX Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy

CompletedCTIS2023-503554-12-00

Bristol Myers Squibb International Corporationlung cancer; kidney cancer; melanoma; liver cancer; colorectal cancer; bladder cancer

Start: 2019-01-09End: 2024-09-12Target: 96Updated: 2024-07-19

Phase 2

A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer

CompletedCTIS2022-502909-15-00

Bristol Myers Squibb International CorporationMetastatic Castration-Resistant Prostate Cancer

Start: 2017-06-09End: 2025-01-07Target: 69Updated: 2024-11-22

Phase 3

A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma

Active, not recruitingCTIS2022-500630-29-00

Bristol-Myers Squibb Services Unlimited CompanySubjects with High Risk Invasive Urothelial Carcinoma

Start: 2016-05-06Target: 165Updated: 2025-10-13